Scientific Program - Dementia
| Section Heads: Murat Emre, Turkey & Alexandre Mendonça, Portugal |
| Please see below the CONy Scientific Program. Please click on the appropriate section to view the relevant program. Please note that the program and timing is subject to change. To view the program timetable / overview, please click here |
| For the full Scientific Program, please click here > |
|
|||
|
Chairs: Virgilio Bento, Portugal; Daniel Ferreira, Sweden |
|||
| 11:00-11:30 |
Can Alzheimer's disease be prevented? |
||
|
Miia Kivipelto, Sweden |
|||
| 11:30-12:00 |
Shifting the paradigm in brain protection and recovery |
||
|
Dafin Muresanu, Romana |
|||
| 14:45-15:15 | |||
|
Tiago Fleming Outeiro, Germany |
|||
| 15:30-16:00 |
AD: Organelles or proteins? |
||
|
Stavros Baloyannis, Greece |
|||
| 16:30-17:00 | Is AD caused by viral infection? | ||
| Ruth Itzhaki, UK | |||
| 17:00-18:00 | Debate: Is beta-amyloid still a relevant target in AD therapy? | ||
| 17:00-17:10 | Host: Michael Geschwind, USA | ||
| 17:10-17:25 | Yes: Paulo Fontoura, Switzerland | ||
| 17:25-17:40 | No: Amos Korczyn, Israel | ||
| 17:40-18:00 | Discussion and rebuttals | ||
|
|||
| 08:30-10:30 | |||
| Chair: Lia Fernandes, Portugal; Teresa Gomez-Isla, USA | |||
| 08:30-09:30 | Debate: Is amyloid imaging really helpful in diagnosing AD? | ||
| Capsule: Beta-amyloid is one of the defining characteristics of AD, however its existence could only be demonstrated by autopsy. New imaging tools can now demonstrate beta-amyloid in vivo, but its existence can also be demonstrated in non-demented individuals | |||
| 08:30-08:40 | Host: Panteleimon Giannakopoulos, Switzerland | ||
| 08:40-08:55 | Yes: Robert Perneczky, UK | ||
| 08:55-09:10 | No: Roger Bullock, UK | ||
| 09:10-09:30 | Discussion and rebuttals | ||
| 09:30-10:30 | Debate: Is imaging of tau the preferable marker of cognitive impairment in AD? | ||
| Capsule: The correlation between NFT and cognitive level is better than that of beta-amyloid. Does that mean that the new imaging modalities, enabling the demonstration of tau deposition by PET, is the new hero? | |||
| 09:30-09:40 | Host: Irena Rektorova, Czech Republic | ||
| 09:40-09:55 | Yes: Panteleimon Giannakopoulos, Switzerland | ||
| 09:55-10:10 | No: Giancarlo Logroscino, Italy | ||
| 10:10-10:30 | Discussion and rebuttals | ||
| 10:45-12:45 | CAUSES OF DEMENTIA | ||
| Chairs: Kobe Abe, Japan, Latchezar Traykov, Bulgaria | |||
| 10:45-11:45 | Debate: Dementia with Lewy bodies and PD dementia: Part of one continum or two distinct entities? | ||
|
Capsule: Patients suffering from PD will develop dementia if they live long enough. In some cases, synuclein deposition in the cortex is associated with cognitive changes before the occurrence of parkinsonism. Are these two different disorders or two presentations of the same disorder? |
|||
| 10:45-10:55 | Host: Lefkos T. Middleton, UK | ||
| 10:55-11:10 | No: Laura Parkkinen, UK | ||
| 11:10-11:25 | Yes: Robert Perneczky, UK | ||
| 11:25-11:45 | Discussion and rebuttals | ||
| 11:45-12:45 | Debate: Amyotrophic laterial sclerosis (ALS) with frontotemporal deficits and FTD - a spectrum or separate entities? | ||
| Capsule: It has long been argued whether ALS is purely a motor disorder or whether patients may also develop cognitive decline. The recent recognition of frontotemporal dementia as a genetic disorder with motor neuron disease features adds a new angle to this question | |||
| 11:45-11:55 | Host: Roger Bullock, UK | ||
| 11:55-12:10 | Separate: Albert Ludolph, Germany | ||
| 12:10-12:25 | Spectrum: Lea Grinberg, USA/Brazil | ||
| 12:25-12:45 | Discussion and rebuttals | ||
| 15:00-17:00 | |||
| Chairs: Horacio Firmino, Portugal; Lev Kruglov, Russia | |||
| 15:00-16:00 | Debate: Is mild cognitive impairments (MCI)-PD a useful concept? | ||
| Capsule: Each PD patient that lives long enough will develop dementia. It is intriguing to speculate whether early treatment may postpone the time for entering into nursing home. New treatments may also be used before the advent of dementia. For this reason it is important to define the early stages of dementia, which may be mild cognitive impairment (MCI). But is MCI-PD really a useful concept? | |||
| 15:00-15:10 | Host: Laura Parkkinen, UK | ||
| 15:10-15:25 | Yes: Jaime Kulisevsky, Spain | ||
| 15:25-15:40 | No: Amos D. Korczyn, Israel | ||
| 15:40-16:00 | Discussion and rebuttals | ||
| 16:00-17:00 |
Debate: Does traumatic chronic encephalopathy (CTE) exist? |
||
|
Capsule: CTE has been defined as a dementing illness casued by phosphorylated tau accumulation in the brain. Its assumed pathogehesis is that concussion or subconcussion initiates a cascade of pathologic events leading to the brain degenderation. However, the role of concussion, whether and how the condition progresses over time, remain to be elucidated |
|||
| 16:00-16:10 | Host: Giancarlo Logroscino, Italy | ||
| 16:10-16:25 | Continuum: Rudolph Castellani, USA | ||
| 16:25-16:40 | Distinct entities: George Perry, USA | ||
| 16:40-17:00 | Discussion and rebuttals | ||
| 17:15-19:00 |
Chair: Edson Amaro, Brazil; Alexandre Mendonca, Portugal |
||
| 17:15-18:10 | Debate: Is NPH over-diagnosed? | ||
| Capsule: What should the requirements be for NPH diagnosis and outcome success? | |||
| 17:15-17:25 | Host: Jaime Kulisevsky, Spain | ||
| 17:25-17:40 | Yes: Michael Geschwind, USA | ||
| 17:40-17:55 | No: Irena Rektorova, Czech Republic | ||
| 17:55-18:10 | Discussion and rebuttals | ||
| 18:10-19:00 | Debate: Does corticobasal degeneration exist as a clinico-pathological entity? | ||
| Capsule: Corticobasal – disease or syndrome? Can we distinguish a real disease from many look-alikes? | |||
| 18:10-18:20 | Host: Ricardo Taipa, Portugal | ||
| 18:20-18:35 | Yes: Néstor Gálvez-Jiménez, USA | ||
| 18:35-18:50 | No: Lea Grinberg, USA/Brazil | ||
| 18:50-19:00 | Discussion and rebuttals | ||
|
|||
|
Chair: Peter Feldschreiber, UK; Jose Leon-Carrion, Spain |
|||
| 10:35-10:55 | Does the diagnosis of AD implies immediate revocation of a driving license? | ||
| Sokratis Papageorgiou, Greece | |||
| 10:55-11:15 | Should vascular dementia be treated with cholinesterase inhibitors? | ||
| Babek Tousi, USA | |||
| 11:15-11:35 | Nanotechnology in early diagnosis and treatment of dementia | ||
| Jerzy Leszek, Poland | |||
|
|||
|
Chairs: Amélia Nogueria Pinto, Portugal; Sadagat Huseynova, Azerbaijan |
|||
| 10:30-11:00 | Beyond the horizon in dementia | ||
| George Perry, USA | |||
| 11:00-11:30 | Beyond the horizon in neuropathology | ||
| Lea Grinberg, USA/Brazil | |||
